PE20130242A1 - Derivados de isoxazolo-piridina - Google Patents

Derivados de isoxazolo-piridina

Info

Publication number
PE20130242A1
PE20130242A1 PE2012002214A PE2012002214A PE20130242A1 PE 20130242 A1 PE20130242 A1 PE 20130242A1 PE 2012002214 A PE2012002214 A PE 2012002214A PE 2012002214 A PE2012002214 A PE 2012002214A PE 20130242 A1 PE20130242 A1 PE 20130242A1
Authority
PE
Peru
Prior art keywords
phenyl
methyl
ilmetoxy
nicotinamide
halogen
Prior art date
Application number
PE2012002214A
Other languages
English (en)
Inventor
Henner Knust
Matthew C Lucas
Roland Jakob-Roetne
Andrew Thomas
Bernd Buettelmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20130242A1 publication Critical patent/PE20130242A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE ISOXAZOLO-PIRIDINA DE FORMULA (I) DONDE X ES O O NH; R1 ES FENILO, PIRIDINILO O PIRIMIDINILO OPCIONALMENTE SUSTITUIDOS CON HALOGENO; R2 ES H, CH3 O CF3; R3, R4, R5 Y R6 SON CADA UNO H, CN, HALOGENO, S(O)-ALQUILO(C1-C7), ALCOXI(C1-C7) OPCIONALMENTE SUSTITUIDO CON HALOGENO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-METIL-6-(5-METIL-3-FENIL-ISOXAZOL-4-ILMETOXI)-NICOTINAMIDA; N-(3-METOXI-PROPIL)-6-(5-METIL-3-FENIL-ISOXAZOL-4-ILMETOXI)-NICOTINAMIDA; N-CICLOPENTIL-6-(5-METIL-3-FENIL-ISOXAZOL-4-ILMETOXI)-NICOTINAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON LIGANDOS DE GABA A a5 SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
PE2012002214A 2007-12-04 2008-12-01 Derivados de isoxazolo-piridina PE20130242A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07122240 2007-12-04

Publications (1)

Publication Number Publication Date
PE20130242A1 true PE20130242A1 (es) 2013-03-04

Family

ID=40329314

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012002214A PE20130242A1 (es) 2007-12-04 2008-12-01 Derivados de isoxazolo-piridina
PE2008002002A PE20091073A1 (es) 2007-12-04 2008-12-01 Derivados de isoxazolo-piridina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2008002002A PE20091073A1 (es) 2007-12-04 2008-12-01 Derivados de isoxazolo-piridina

Country Status (34)

Country Link
US (6) US20090143371A1 (es)
EP (2) EP2767536B1 (es)
JP (1) JP5301557B2 (es)
KR (2) KR20120102117A (es)
CN (1) CN101889010B (es)
AR (1) AR069523A1 (es)
AU (1) AU2008333326B2 (es)
BR (1) BRPI0820112B8 (es)
CA (1) CA2707648C (es)
CL (1) CL2008003591A1 (es)
CO (1) CO6351788A2 (es)
CR (1) CR11454A (es)
CY (2) CY1116119T1 (es)
DK (2) DK2767536T3 (es)
EC (1) ECSP10010230A (es)
ES (2) ES2531023T3 (es)
HK (1) HK1149756A1 (es)
HR (2) HRP20150348T1 (es)
HU (1) HUE025545T2 (es)
IL (1) IL205759A (es)
MA (1) MA31865B1 (es)
MX (1) MX2010005717A (es)
MY (1) MY156747A (es)
NZ (1) NZ585308A (es)
PE (2) PE20130242A1 (es)
PL (2) PL2767536T3 (es)
PT (2) PT2767536E (es)
RS (2) RS54355B1 (es)
RU (1) RU2484091C2 (es)
SI (2) SI2227467T1 (es)
TW (1) TWI363624B (es)
UA (1) UA100132C2 (es)
WO (1) WO2009071476A1 (es)
ZA (1) ZA201003631B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008333326B2 (en) 2007-12-04 2013-05-30 F. Hoffmann-La Roche Ag Isoxazolo-pyridine derivatives
MX2011004125A (es) * 2008-10-21 2011-05-19 Metabolex Inc Agonistas del receptor gpr120 de arilo y usos de los mismos.
EP2942346B1 (en) 2009-02-17 2020-05-06 Syntrix Biosystems, Inc. Pyridinecarboxamides as cxcr2 modulators
US8389550B2 (en) * 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) * 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US20100280019A1 (en) 2009-04-30 2010-11-04 Roland Jakob-Roetne Isoxazoles
EP2427455B1 (en) * 2009-05-05 2020-01-15 F.Hoffmann-La Roche Ag Isoxazole-pyrazole derivatives
US8415379B2 (en) * 2009-05-05 2013-04-09 Hoffmann-La Roche Inc. Pyridines
KR101354335B1 (ko) * 2009-05-05 2014-02-19 에프. 호프만-라 로슈 아게 인지 장애의 치료에 사용되는 ｇａｂａ ａ 수용체 역 작용제로서의 아이속사졸-티아졸 유도체
MX2011011484A (es) * 2009-05-07 2011-11-18 Hoffmann La Roche Derivados de isoxazol-piridina como moduladores del acido gamma-aminobutirico.
CA2774981A1 (en) * 2009-09-21 2011-03-24 Vanderbilt University O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators
CA2787785C (en) 2010-01-28 2018-03-06 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
US20130252972A1 (en) 2010-07-19 2013-09-26 Syngenta Crop Protection Llc Isoxazole, isothiazole, furane and thiophene compounds as microbicides
CN103003265A (zh) 2010-07-19 2013-03-27 先正达参股股份有限公司 杀微生物剂
WO2012027289A1 (en) 2010-08-23 2012-03-01 Syntrix Biosystems Inc. Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
US8835425B2 (en) * 2010-11-05 2014-09-16 Hoffmann-La Roche Inc. Use of selective GABA A α5 negative allosteric modulators for the treatment of central nervous system conditions
EP2457569A1 (en) 2010-11-05 2012-05-30 F. Hoffmann-La Roche AG Use of active pharmaceutical compounds for the treatment of central nervous system conditions
JP6208122B2 (ja) 2011-05-12 2017-10-04 プロテオステイシス セラピューティクス，インコーポレイテッド プロテオスタシス調節因子
US8604062B2 (en) * 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
US8785435B2 (en) * 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
DK3141542T3 (da) 2011-12-28 2020-08-10 Global Blood Therapeutics Inc Substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsiltning
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
AU2013283488A1 (en) 2012-06-26 2015-01-15 Saniona Aps A phenyl triazole derivative and its use for modulating the GABAA receptor complex
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
EP2877463B1 (en) * 2012-06-26 2018-11-07 Saniona A/S A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201591426A1 (ru) 2013-03-15 2016-02-29 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN112500338A (zh) 2013-03-15 2021-03-16 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
PE20151900A1 (es) * 2013-03-15 2016-01-20 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
EP3102208B1 (en) 2014-02-07 2021-01-13 Global Blood Therapeutics, Inc. Crystalline polymorph of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
JP2017071553A (ja) * 2014-02-25 2017-04-13 味の素株式会社 ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
CN106810542B (zh) * 2015-11-30 2021-03-09 苏州开拓药业股份有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法
SG11201804647TA (en) 2015-12-04 2018-06-28 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
CR20190268A (es) * 2016-12-08 2019-07-11 Hoffmann La Roche Nuevos deribados de isoxazolil éter como pam de gaba a alfa5
US11459320B2 (en) 2017-08-28 2022-10-04 University Of Maryland, Baltimore Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type A receptors as fast acting treatment for depression and mood disorders
UY38031A (es) * 2017-12-22 2019-07-31 Bayer Ag Hidroxiisoxazolinas y derivados de estos
WO2019238633A1 (en) 2018-06-13 2019-12-19 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as gaba a alpha5 pam
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
EP4126858A1 (en) 2020-03-26 2023-02-08 Richter Gedeon Nyrt. Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
EP4334301A1 (en) 2021-05-05 2024-03-13 University College Cardiff Consultants Limited Heteroaryl compounds useful in the treatment of cognitive disorders
CN116854680A (zh) * 2022-03-28 2023-10-10 上海赛默罗生物科技有限公司 异噁唑-杂环类衍生物、药物组合物和用途
CN115286636A (zh) * 2022-10-08 2022-11-04 上海赛默罗生物科技有限公司 烟酰胺晶型及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812225A1 (de) * 1988-04-13 1989-10-26 Basf Ag Isoxazol(isothiazol)-5-carbonsaeureamide
DE69929345T2 (de) * 1998-08-07 2006-09-21 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Substituierte isoxal-derivate als östrogenrezeptormodulatoren
DE19920791A1 (de) * 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
GB0125086D0 (en) 2001-10-18 2001-12-12 Merck Sharp & Dohme Novel compounds
EP1513817A1 (en) 2002-05-24 2005-03-16 Takeda Pharmaceutical Company Limited 1, 2-azole derivatives with hypoglycemic and hypolipidemic activity
GB0221443D0 (en) * 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
RU2408589C2 (ru) * 2004-05-14 2011-01-10 Айрм Ллк Соединения и композиции в качестве модуляторов ppar-рецепторов, активируемых пролифератором пероксисом
ES2315912T3 (es) * 2004-10-01 2009-04-01 F. Hoffmann-La Roche Ag Derivados de eter sustituido por hexafluorisopropanol.
ES2352796T3 (es) * 2005-06-27 2011-02-23 Bristol-Myers Squibb Company Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas.
BRPI0616184A2 (pt) * 2005-09-19 2011-06-07 Hoffmann La Roche derivados de isoxazolo como agonistas inversos gaba a alfa 5, processo para a preparação dos mesmos, medicamento e uso dos referidos derivados
EP1937674A1 (en) * 2005-10-11 2008-07-02 F.Hoffmann-La Roche Ag Isoxazole derivatives
AU2006328602B2 (en) * 2005-12-23 2012-05-31 F. Hoffmann-La Roche Ag Aryl-isoxazolo-4-yl-oxadiazole derivatives
EP1968977B1 (en) 2005-12-27 2011-12-14 F. Hoffmann-La Roche AG Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives
WO2007074078A2 (en) 2005-12-27 2007-07-05 F. Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazole derivatives
EP1979350A1 (en) 2006-01-17 2008-10-15 F.Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of alzheimer's disease via gaba receptors
JP5301556B2 (ja) 2007-12-04 2013-09-25 エフ．ホフマン−ラ ロシュ アーゲー イソオキサゾロ−ピラジン誘導体
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
AU2008333326B2 (en) 2007-12-04 2013-05-30 F. Hoffmann-La Roche Ag Isoxazolo-pyridine derivatives
US20100280019A1 (en) * 2009-04-30 2010-11-04 Roland Jakob-Roetne Isoxazoles

Also Published As

Publication number Publication date
US9073908B2 (en) 2015-07-07
EP2767536A1 (en) 2014-08-20
US20130274467A1 (en) 2013-10-17
EP2767536B1 (en) 2015-09-02
PT2767536E (pt) 2015-11-17
US20130281690A1 (en) 2013-10-24
DK2767536T3 (en) 2015-10-19
EP2227467A1 (en) 2010-09-15
US20130274468A1 (en) 2013-10-17
RS53877B1 (en) 2015-08-31
SI2767536T1 (sl) 2015-12-31
PL2227467T3 (pl) 2015-05-29
HUE025545T2 (en) 2016-03-29
US20120184538A1 (en) 2012-07-19
AU2008333326B2 (en) 2013-05-30
ES2531023T3 (es) 2015-03-09
ES2550994T3 (es) 2015-11-13
CN101889010A (zh) 2010-11-17
HRP20150348T1 (hr) 2015-05-08
US8877783B2 (en) 2014-11-04
WO2009071476A1 (en) 2009-06-11
TWI363624B (en) 2012-05-11
CN101889010B (zh) 2012-12-05
CA2707648C (en) 2014-08-12
HRP20151250T1 (hr) 2015-12-18
KR101237576B1 (ko) 2013-03-04
BRPI0820112B1 (pt) 2019-01-15
IL205759A0 (en) 2010-11-30
TW200924763A (en) 2009-06-16
JP2011505401A (ja) 2011-02-24
CY1116902T1 (el) 2017-04-05
PE20091073A1 (es) 2009-07-23
PT2227467E (pt) 2015-03-02
HK1149756A1 (en) 2011-10-14
JP5301557B2 (ja) 2013-09-25
CL2008003591A1 (es) 2010-01-04
MY156747A (en) 2016-03-31
UA100132C2 (en) 2012-11-26
US20130274469A1 (en) 2013-10-17
DK2227467T3 (en) 2015-01-19
US8518974B2 (en) 2013-08-27
US8877782B2 (en) 2014-11-04
RS54355B1 (en) 2016-04-28
BRPI0820112B8 (pt) 2021-05-25
PL2767536T3 (pl) 2016-01-29
IL205759A (en) 2014-07-31
NZ585308A (en) 2012-03-30
KR20100075669A (ko) 2010-07-02
MX2010005717A (es) 2010-06-02
ECSP10010230A (es) 2010-07-30
SI2227467T1 (sl) 2015-03-31
CO6351788A2 (es) 2011-12-20
AR069523A1 (es) 2010-01-27
BRPI0820112A2 (pt) 2015-05-05
US20090143371A1 (en) 2009-06-04
US8846719B2 (en) 2014-09-30
RU2010123923A (ru) 2012-01-10
CR11454A (es) 2010-06-28
AU2008333326A1 (en) 2009-06-11
EP2227467B1 (en) 2014-12-31
CA2707648A1 (en) 2009-06-11
CY1116119T1 (el) 2017-02-08
ZA201003631B (en) 2013-10-30
KR20120102117A (ko) 2012-09-17
MA31865B1 (fr) 2010-11-01
RU2484091C2 (ru) 2013-06-10

Similar Documents

Publication Publication Date Title
PE20130242A1 (es) Derivados de isoxazolo-piridina
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20070528A1 (es) Compuestos heterociclicos como ligandos del receptor vaniloide del subtipo 1
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
PE20081755A1 (es) Nuevas 2-aminooxazolinas como ligandos taar1
PE20090982A1 (es) Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
PE20061377A1 (es) Compuestos heterociclicos fusionados
ATE517874T1 (de) Pyrimidinone als modulatoren von caseinkinase ii (ck2)
MX2009004467A (es) Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk).
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
AP2002002578A0 (en) Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses.
PE20070069A1 (es) Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
SE0401970D0 (sv) Novel compounds
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
EA200602180A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина для применения при лечении аффективных расстройств, боли, нгдв и стрессового недержания мочи
ATE435223T1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate

Legal Events

Date Code Title Description
FC Refusal